艾塞那肽与胰腺炎：最新进展 - Suppr

Suppr

超能文献

Exenatide and pancreatitis: an update.

作者信息

Bain Steve C, Stephens Jeffrey W

出版信息

Expert Opin Drug Saf. 2008 Nov;7(6):643-4. doi: 10.1517/14740330802432003.

DOI:10.1517/14740330802432003

PMID:18983211

Abstract

摘要

相似文献

Exenatide and pancreatitis: an update.

Expert Opin Drug Saf. 2008 Nov;7(6):643-4. doi: 10.1517/14740330802432003.

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.

Gastroenterology. 2011 Jul;141(1):150-6. doi: 10.1053/j.gastro.2011.02.018. Epub 2011 Feb 18.

Exenatide (exendin-4)-induced pancreatitis: a case report.

Diabetes Care. 2006 Feb;29(2):471. doi: 10.2337/diacare.29.02.06.dc05-2043.

A cohort study of acute pancreatitis in relation to exenatide use.

Diabetes Obes Metab. 2011 Jun;13(6):559-66. doi: 10.1111/j.1463-1326.2011.01376.x.

Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study.

Diabet Med. 2012 Nov;29(11):1412-8. doi: 10.1111/j.1464-5491.2012.03652.x.

Exenatide and acute pancreatitis.

J Assoc Physicians India. 2008 Dec;56:987-8.

Exenatide and sitagliptin: pancreatitis and pancreatic cancer. Harms on the rise.

Prescrire Int. 2011 Nov;20(121):267.

Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population.

Diabetes Technol Ther. 2012 Oct;14(10):904-11. doi: 10.1089/dia.2012.0075. Epub 2012 Jul 30.

A pooled analysis of exenatide use and risk of acute pancreatitis.

Curr Med Res Opin. 2013 Dec;29(12):1577-86. doi: 10.1185/03007995.2013.838550. Epub 2013 Sep 13.

Exenatide and rare adverse events.

N Engl J Med. 2008 May 1;358(18):1970-1; discussion 1971-2.

引用本文的文献

Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis.

Int J Clin Pharm. 2023 Jun;45(3):689-697. doi: 10.1007/s11096-023-01556-2. Epub 2023 Mar 28.

Hepatic HAX-1 inactivation prevents metabolic diseases by enhancing mitochondrial activity and bile salt export.

J Biol Chem. 2020 Apr 3;295(14):4631-4646. doi: 10.1074/jbc.RA119.012361. Epub 2020 Feb 20.

Incretins and the intensivist: what are they and what does an intensivist need to know about them?

Crit Care. 2014 Feb 20;18(2):205. doi: 10.1186/cc13737.

Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies.

Diabetes Ther. 2013 Jun;4(1):119-45. doi: 10.1007/s13300-013-0024-0. Epub 2013 May 23.

Emerging role of GLP-1 receptor agonists in the treatment of obesity.

Diabetes Metab Syndr Obes. 2010 Jul 20;3:263-73. doi: 10.2147/dmsott.s6816.

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus.

Diabetes Metab Syndr Obes. 2010 May 17;3:165-72. doi: 10.2147/dmsott.s7493.

Novel treatments for type 2 diabetes.

Br J Gen Pract. 2011 Jan;61(582):5-6. doi: 10.3399/bjgp11X548884.

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.

Int J Clin Pract. 2010 Jun;64(7):984-90. doi: 10.1111/j.1742-1241.2010.02382.x. Epub 2010 Apr 14.

Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives.

Patient Prefer Adherence. 2010 Mar 24;4:61-8. doi: 10.2147/ppa.s6358.

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis.

Diabetologia. 2010 Jul;53(7):1258-69. doi: 10.1007/s00125-010-1702-3. Epub 2010 Mar 31.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Exenatide and pancreatitis: an update.

作者信息

Bain Steve C, Stephens Jeffrey W

出版信息

Expert Opin Drug Saf. 2008 Nov;7(6):643-4. doi: 10.1517/14740330802432003.

DOI:10.1517/14740330802432003

PMID:18983211

Abstract

摘要

相似文献

Exenatide and pancreatitis: an update.

Expert Opin Drug Saf. 2008 Nov;7(6):643-4. doi: 10.1517/14740330802432003.

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.

Gastroenterology. 2011 Jul;141(1):150-6. doi: 10.1053/j.gastro.2011.02.018. Epub 2011 Feb 18.

Exenatide (exendin-4)-induced pancreatitis: a case report.

Diabetes Care. 2006 Feb;29(2):471. doi: 10.2337/diacare.29.02.06.dc05-2043.

A cohort study of acute pancreatitis in relation to exenatide use.

Diabetes Obes Metab. 2011 Jun;13(6):559-66. doi: 10.1111/j.1463-1326.2011.01376.x.

Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study.

Diabet Med. 2012 Nov;29(11):1412-8. doi: 10.1111/j.1464-5491.2012.03652.x.

Exenatide and acute pancreatitis.

J Assoc Physicians India. 2008 Dec;56:987-8.

Exenatide and sitagliptin: pancreatitis and pancreatic cancer. Harms on the rise.

Prescrire Int. 2011 Nov;20(121):267.

Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population.

Diabetes Technol Ther. 2012 Oct;14(10):904-11. doi: 10.1089/dia.2012.0075. Epub 2012 Jul 30.

A pooled analysis of exenatide use and risk of acute pancreatitis.

Curr Med Res Opin. 2013 Dec;29(12):1577-86. doi: 10.1185/03007995.2013.838550. Epub 2013 Sep 13.

Exenatide and rare adverse events.

N Engl J Med. 2008 May 1;358(18):1970-1; discussion 1971-2.

引用本文的文献

Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis.

Int J Clin Pharm. 2023 Jun;45(3):689-697. doi: 10.1007/s11096-023-01556-2. Epub 2023 Mar 28.

Hepatic HAX-1 inactivation prevents metabolic diseases by enhancing mitochondrial activity and bile salt export.

J Biol Chem. 2020 Apr 3;295(14):4631-4646. doi: 10.1074/jbc.RA119.012361. Epub 2020 Feb 20.

Incretins and the intensivist: what are they and what does an intensivist need to know about them?

Crit Care. 2014 Feb 20;18(2):205. doi: 10.1186/cc13737.

Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies.

Diabetes Ther. 2013 Jun;4(1):119-45. doi: 10.1007/s13300-013-0024-0. Epub 2013 May 23.

Emerging role of GLP-1 receptor agonists in the treatment of obesity.

Diabetes Metab Syndr Obes. 2010 Jul 20;3:263-73. doi: 10.2147/dmsott.s6816.

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus.

Diabetes Metab Syndr Obes. 2010 May 17;3:165-72. doi: 10.2147/dmsott.s7493.

Novel treatments for type 2 diabetes.

Br J Gen Pract. 2011 Jan;61(582):5-6. doi: 10.3399/bjgp11X548884.

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.

Int J Clin Pract. 2010 Jun;64(7):984-90. doi: 10.1111/j.1742-1241.2010.02382.x. Epub 2010 Apr 14.

Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives.

Patient Prefer Adherence. 2010 Mar 24;4:61-8. doi: 10.2147/ppa.s6358.

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis.

Diabetologia. 2010 Jul;53(7):1258-69. doi: 10.1007/s00125-010-1702-3. Epub 2010 Mar 31.